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PENCIRIAN FRAKSI PIAWAI Clinacanthus nutans (SF1) DAN KESAN ANTI 
TUMOR TERHADAP MODEL IN VITRO DAN XENOGRAF  
 
ABSTRAK 
 Kanser serviks adalah penyebab utama kematian wanita di dunia dan ketiga di 
Malaysia. Kini, tumbuhan perubatan menjadi rawatan alternatif yang popular kerana 
kesan sampingan rawatan moden dan mudah didapati. Clinacanthus nutans (C. nutans) 
telah dikenal pasti dan dipercayai oleh penduduk tempatan sebagai alternatif kepada 
rawatan kanser. Menurut kajian awal, satu fraksi dari C. nutans telah menunjukkan 
perencatan yang aktif terhadap kanser serviks manusia, in vitro. Oleh itu, kajian ini 
dijalankan untuk mengenal pasti sebatian antikanser aktif dari C. nutans dan menentukan 
kesan penindasan tumor bersama mekanisme untuk menilai potensi C. nutans sebagai 
rawatan alternatif untuk kanser serviks. Mulanya, pengoptimuman fraksinasi berpandu 
bioassai telah dijalankan. Semua fraksi C. nutans yang terkumpul diperiksa untuk aktiviti 
sitotoksik ke atas sel kanser servik manusia HeLa dan SiHa dan sel normal, NIH, oleh 
Assai MTT. Fraksi piawai yang paling berpotensi, SF1 dicirikan dan dikenal pasti oleh 
Fourier Transform Infrared (FTIR), Spektrometer Jisim Kromatografi Liquid (LCMS) 
dan analisa fitokimia kuantitatif. Mekanisme antikanser SF1 dinilai oleh analisa sitometri 
aliran untuk perkembangan kitaran sel, mod kematian sel dan ekspresi protein 
menggunakan pewarnaan berganda Annexin-V/propidium iodida dan antibodi khusus 
berkonjugat; Bax, Bcl-2, p53 dan cytochrome C. Penyiasatan lanjut terhadap kesan 
penindasan tumor dijalankan menggunakan tikus nude xenograf sebagai model subjek 
hidup. Tikus telah diinduksikan dengan sel SiHa. Apabila isipadu tumor mencapai 100 
mm3, rawatan SF1 diberikan sekali sehari secara suntikan intraperitoneal, selama 28 hari. 




(H&E) dan imunohistokimia (IHC) menggunakan caspase-3. Darah dikumpulkan untuk 
penilaian tahap aspartat aminotransferase (AST) dan alanine aminotransferase (ALT). 
Penemuan ini mencadangkan bahawa konstituen utama SF1 dikenal pasti sebagai 
sebatian alkaloid dengan amina sebagai kumpulan berfungsi. Rawatan SF1 menunjukkan 
sitotoksiksiti yang lebih baik dengan perencatan pertumbuhan terbaik terhadap SiHa sel 
(IC50 = 9.98±1.24 µg/ml) berbanding HeLa sel (IC50 = 81.21±1.17 µg/ml) dan 
menunjukkan sitoselektif dengan tiada IC50 dikesan ke atas NIH. SF1 mengaruh apoptosis 
awal dalam proliferasi sel SiHa dengan merencat sel di titik kawalan G1/S. Peningkatan 
p53 diikuti dengan peningkatan pro-apoptosis Bax dan penurunan anti-apoptosis Bcl-2 
serta peningkatan tahap cytochrome C selepas rawatan dengan SF1 juga dibuktikan. Hasil 
kajian juga menunjukkan bahawa isipadu tumor dalam tikus SF1 (60.18±2.17 mm3) yang 
dirawat berkurangan berbanding dengan kawalan negatif (139.16±12.97 mm3). Selepas 
rawatan SF1, 43.74% nisbah pertumbuhan tumor relatif (T/C) dan 0.64 ± 0.03 daripada 
isipadu tumor relatif (RTV) telah dikira. SF1 menunjukkan kadar perencatan yang baik 
dengan lebih daripada 50% tumor ditindas. Tahap ALT dan AST dalam tikus SF1 yang 
dirawat kekal dalam julat normal berbanding kumpulan sisplatin yang menunjukkan 
kesan toksik. Analisa H&E menunjukkan tiada ketoksikan yang abnormal pada hati dan 
pengurangan mitosis pada tumor apabila dirawat dengan SF1. Analisa IHC mengesahkan 
peningkatan ekspresi pengantara penting bagi apoptosis, caspase-3, dalam tikus yang 
dirawat SF1. Kesimpulannya, SF1 menunjukkan aktiviti antikanser dengan mengaruh 
apoptosis melalui penahanan kitaran sel di titik kawalan G1/S melalui tapak jalan p53 
diperantara mitokondria. Kesan penindasan tumor SF1 ditunjukkan pada perkembangan 
kanser serviks manusia xenograft dalam tikus nude. Oleh itu, penemuan ini menyediakan 




CHARACTERISATION OF STANDARDISED FRACTION FROM Clinacanthus 




 Cervical cancer is a leading cause of death in women, worldwide, and third in 
Malaysia. Nowadays, medicinal plants become an alternative treatment due to side effects 
of conventional treatment and easily available. Clinacanthus nutans has been locally 
recognized and was claimed for cancer treatment. From our pilot study, a fraction of C. 
nutans shown a potent inhibition on human cervical cancer cells, in vitro. Therefore, this 
study was conducted to characterize active anticancer compounds from C. nutans and 
determine tumor suppression effect with its mechanism in order to evaluate the potential 
of C. nutans as an alternative treatment for cervical cancer. Initially, optimization 
methods of bioassay-guided fractionation was carried out. All collected fractions of C. 
nutans were examined for cytotoxic activity towards human cervical cancer cell lines, 
HeLa and SiHa, and normal cell line, NIH by MTT Assay. The most potent standardized 
fraction, SF1 was characterised and identified by Fourier Transform Infrared (FTIR), 
Liquid Chromatography Mass Spectrometer (LCMS) and quantitative phytochemical 
analysis. The anticancer mechanism of SF1 was evaluated by flowcytometric analysis for 
cell cycle progression, mode of cell death and protein expression using Annexin-
V/propidium iodide double staining and specific antibody conjugated fluorescent dye; 
Bax, Bcl-2, p53 and cytochrome C. Further investigation of SF1 on tumor suppression 
effect was conducted using xenografted nude mice as a model of living subject. The nude 
mice were subcutaneously inoculated with SiHa cells. Tumor volume and body weight 




administered once daily via intraperitoneal injection for 28 days. Tumor and liver were 
surgically removed and fixed for hematoxylin and eosin (H&E) staining and 
immunohistochemistry (IHC) using caspase-3. Blood was collected by cardiac puncture 
for assessment of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 
level. The findings suggested that the major constituent of SF1 was identified as alkaloid 
with functional group, amines. SF1 exhibited better cytotoxicity with best growth 
inhibition against SiHa (IC50 = 9.98±1.24 µg/ml) compared to HeLa (IC50 = 81.21±1.17 
µg/ml) and showed cytoselectivity with no IC50 detected on NIH cells. SF1 induced early 
apoptosis in SiHa cells with arrested cell cycle at G1/S checkpoint. Up-regulation of p53 
followed by increasing of pro-apoptotic Bax and decreasing of anti-apoptotic Bcl-2 as 
well as increment of cytochrome C levels upon treatment with SF1 were also shown. The 
results showed that tumor volume (60.18±2.17 mm3) in SF1-treated mice were reduced 
compared to negative control (139.16±12.97 mm3). Upon SF1 treatment, 43.74± 2.27% 
of relative tumor growth ratio (T/C) and 0.64±0.03 of relative tumor volume (RTV) were 
calculated. SF1 showed a good inhibition rate with more than 50% of tumor were 
suppressed. ALT and AST level in SF1-treated mice were remained in normal ranges 
compared to cisplatin group indicating no sign of toxicity effects. The H&E analysis 
revealed no abnormal toxicity condition on liver and reduced number of mitosis on tumor 
upon treatment with SF1. The IHC analysis confirmed an increased expression of a 
crucial mediators of apoptosis, caspase-3, in SF1-treated mice. In conclusion, SF1 
demonstrated anticancer activity by inducing apoptosis through arrested G1/S cell cycle 
checkpoint via p53 mediated mitochondrial pathway. The tumor suppression effect of 
SF1 was demonstrated on the growth of xenografted human cervical cancer in nude mice. 
Thus, these findings provided a data for a potential of SF1 as future therapeutic drug for 







1.1 Background of study 
 
 Malaysia is among developing countries that going through rapid transformation 
of social life and economic changes. This situation has led to improvement of lifestyles 
that usually occur to other industrialised countries. As consequences, cancer diseases rises 
as one of the major health threats related to quality of life in this world. Habli et al. (2017) 
stated that, rise of prevalence in cancer has captured attention of researchers who have 
been determined to find and develop better and effective treatments.  
 
 For the past decades ago, cervical cancer has been the most common types of 
gynecological cancer malignancies worldwide (Zhen et al., 2016). It is the third most 
common cancer among females in Malaysia, after breast and colorectal cancer (Bruni et 
al., 2018; Zaridah, 2014; Othman, 2003). The current treatment of cervical cancer are 
surgical removal of certain reproductive organs and radiotherapy with the help of 
chemotherapy. Those treatments has remain first option to treat cervical cancer. However, 
these approaches are limited by resistance, toxicity to surrounding healthy cells in body 
and expensive operation.  
 
 Currently, many anticancer drugs has been developed using medicinal plants in 
both traditional and modern medicine (He et al., 2017; Ghasemzadeh et al., 2014). The 
use of natural sources in cancer treatment have been applied extensively by many 
Malaysian old folks to improve survivorship. The medicinal plants have been an asset to 




World Health Organization (WHO) reported that in developing countries such as 
Malaysia, 85% of people utilised traditional medicines derived from medicinal plants for 
their primary health care (World Health Organization, 2017). This positive trend could 
be due to resistance towards commercial anticancer drugs and existence of certain side 
effects of current cancer treatment. In fact, medicinal plants constitutes largest and 
valuable sources of natural products that have been proven potent against various disease 
including cancer (Habli et al., 2017; Alam et al., 2016). Therefore, new and safe drugs 
that originated from medicinal plants are necessary in order to improve standard 
treatments, in vitro and in vivo.  
 
1.2 Rationale of study  
 
 With the current trend, it is important to extensively develop a cure for cervical 
cancer from common medicinal plants that have been locally utilised. This is due to many 
cancer patients believed the effect of medicinal plants that can improve survivorship and 
offer better lifestyle upon diagnosed with the disease. In this study, C. nutans has been 
used based on traditional claim from our old folks in combating cancer and easily 
available (Alam et al., 2016; P’ng et al., 2013; Hariana, 2013).  
 
 Based on our pilot study, one of the active fraction from C. nutans namely F11 
was able to inhibit proliferation of cervical cancer cells, HeLa (Roslan et al., 2018). 
Initially, bioassay guided fractionation was carried out using column chromatography and 
several fractions were collected. All fractions were tested for cytotoxicity test by MTT 
Assay. F11 was found as the most potent fraction from the elution of ethyl acetate : hexane 
(1 : 1) by inhibiting the growth of HeLa cells at G1 phase. This indicate that the cell 




the aim of the present study were to further characterize F11 and its anticancer 
mechanism, in vitro and in vivo, in order to evaluate the potential of C. nutans as an 
alternative treatment for cervical cancer.  
 
 The findings of this study could have provide proper guidance and support the 
traditional knowledge of local people in using C. nutans for cervical cancer treatment. It 
is also provide new knowledge about the bioactive compound from local plant that have 
medicinal properties of anticancer. With increasing concern of cancer chemoprevention 
from herbal medicinal plant, the utilization of local medicinal plant in Malaysia such as 
C. nutans might have beneficial effect towards cancer treatment.  
 
1.2.1 Hypothesis of study 
 
 This current study was conducted to serve as a fundamental basis to further govern 
the characterisation of SF1, an active anticancer fraction derived from C. nutans and to 
study its tumor suppression effect. The anticancer mechanism will be investigated in 
order to evaluate the potential of SF1 as an alternative treatment for cervical cancer. At 
the end of this study, the findings in between biological activities, in vitro apoptosis study, 
in vivo tumor suppression effects and characterisation of C. nutans, specifically SF1, with 
anticancer properties will be elucidated. Thus, the anticancer mechanism of SF1 and its 
effectiveness will provide updated knowledge and information towards cancer treatment. 
In future, if it is proven to be effective and potent towards cervical cancer treatment, a 
new potential alternative drug for anticancer could be further formulated and developed 





1.3 Objectives of study 
 
1.3.1 General Objective 
 
To characterize active anticancer compounds from C. nutans and determine the 
tumor suppression effect with its anticancer mechanism in order to evaluate the 
potential of C. nutans as an alternative potential treatment for cervical cancer  
 
1.3.2 Specific Objectives 
 
1) To characterize the active fraction extracted from the leaves of C. nutans which 
responsible for anticancer activity using Fourier Transform Infra-Red (FTIR), 
Liquid Chromatography Mass Spectrophotometry (LCMS) and quantitative 
phytochemical analysis 
2) To determine the cytotoxic activity of active fraction from the leaves of C. nutans 
towards human cervical carcinoma by comparing with non-cancerous cell lines 
using MTT Assay 
3) To investigate the mechanism of anticancer effect of active fraction from the 
leaves of C. nutans using flowcytometry, with observation of cell cycle profile, 
measurement of mode of cell death and detection of apoptotic protein, in vitro.  
4) To further investigate the anti tumor effect of active fraction from the leaves of C. 
nutans using xenograft model, with observation of tumor suppression effect, 












 In 2017, the International Agency Research on Cancer (IARC), the specialised 
cancer agency of WHO reported more than 14 million new cancer cases and almost 10 
million cancer-related deaths in its online database, GLOBOCAN. More than half of all 
cancer cases and cancer deaths in 2015 occurred in developing countries. Tremendous 
efforts have been put into developing a cure for this disease, but the number of cancer 
patients remain higher and increases as new cases arises annually. This percentage is 
predicted to be increase by 2025 (International Agency for Research on Cancer, 2018). 
Experts have anticipated that the main cause of this disease has been due to rapid 
uncontrollable multiplication and spreading of abnormal cells. This phenomenon is 
caused by mutation that constantly emerge in the genome of cancer cells during cells 
division (Habli et al., 2017).  
 
2.2 Cervical cancer  
 
 The cervix is a cylindrical structure composed of stroma and epithelium, located 
at the lowermost part of the uterus. WHO reported that cancer of the cervix uteri is the 
fourth most common cancer among women with 284,823 women being diagnosed with 
cervical cancer and 144,434 dying from the disease worldwide, annually (Bruni et al., 
2018). In Asia, this type of cancer ranks the third most frequent cancer among women 
(Bruni et al., 2018). An estimated population of 1673.2 million women aged 15 years and 




of Malaysia (NCSM) reported that cervical cancer is the third most common cancer 
among women and the fourth leading cause of death in women aged between 15 and 44 
years old, in Malaysia (Zaridah, 2014; Indramalar, 2015). In Malaysia, although screening 
and immunisation programmes have been widely implemented, the mortality rate due to 
cervical cancer is still higher than United Kingdom’s (Zaridah, 2014).  
 
 Cervical cancer is usually characterised by a premalignant condition known as 
cervical intraepithelial neoplasia (Tsao et al., 2004). Among the major factors 
contributing to cervical cancer is human papillomavirus (HPV) infection such as HPV 
16, 18, 31, 33, 35, 45, 52 and 58. However, almost 70% of the cancers worldwide 
comprise squamous cell carcinoma, HPV 16 and followed by adenocarcinoma, HPV 18, 
worldwide (Bruni et al., 2018; Zaridah, 2014; Choudari et al., 2013). Due to this 
prevalence scenario, two types of cervical cancer cell lines which are HeLa (HPV 18) and 
SiHa (HPV 16), were used throughout this study. Figure 2.1 showed simplified 
illustrations on genomic difference between HPV 16 and HPV 18. The prevalence of HPV 
increases with lesion severity of 41% - 67% high-grade cervical lesions and 16% - 32% 
low-grade cervical lesions (Bhatla et al., 2018). The majority of HPV infections resolve 
spontaneously and do not cause symptoms or diseases. However, Zaridah (2014) reported 
that persistent infection with specific types of HPV, most frequently types 16 and 18, 
usually leads to precancerous lesions. Cervical cancer is a potentially preventable disease. 
However, certain kinds of lesion may develop into cervical cancer if no further treatment 
or precaution is taken.  
 
 The genome of HPV is a circular double-stranded DNA molecule of 
approximately 8000 base pairs (Saito and Kiyono, 2007).  Bruni et al. (2018) reported 




vagina and penis, although the information is limited compared to cervical cancer. The 
HPV viral oncogenes, E6 and E7 have been shown to be the main contributors to the 
development of HPV-induced cervical cancer and increased expression. This happened 
probably due to integration of the viral DNA in the host cell genome which has been 
detected in invasive cancers and a subset of high-grade lesions (Saito and Kiyono, 2007). 
Both E6 and E7 HPV oncogenes interact and inhibit the activities of tumor suppressors 
by inactivate the action of tumor suppressor p53 and/or retinoblastoma protein (pRB) as 
shown in Figure 2.2 which adapted from Burd (2003).  
 
 Generally, anal cancers are predominantly squamous cell carcinoma, 
adenocarcinoma and basaloid carcinomas, while vulvar cancers represent the majority of 
the vulvar lesions which occur more often in older women and rarely associated with 
HPV (Bruni et al., 2018). Most vaginal cancers are squamous cell carcinoma, which is 
generally attributable to HPV, followed by clear cell adenocarcinomas and melanoma. In 
most cases, metastatic cervical cancer usually has been misclassified as vaginal cancer 
(Bruni et al., 2018; Bhatla et al., 2018).  
 
 With this alarming situation, there is an urgent need to prevent the increment of 
cervical cancer case by developing potent and economical approaches for early detection 











HPV 16 HPV 18 
  
 
Figure 2.1 Simplified illustrations on genomic difference between HPV 16 and HPV 18 
where URR : regulation of virus gene expression & virus replication; L1 : 
major capsid protein; L2 : minor capsid protein E1 : DNA replication; E2 : 
replication and transcription; E4 : viral release; E5 : immune evasion; E6 : 
binds p53; E7 : binds pRB (Adapted from Shanmugasundaram, S. & You, J. 










Figure 2.2 Pathogenesis of oncogenic HPV where HPV E6 and E7 genes encode 
multifunctional proteins that bind primarily to cellular p53 and pRB proteins, 
disrupt their functions, and alter cell cycle regulatory pathways, leading to 















2.2.1 Treatment of cervical cancer 
 
 Generally, the treatment of cervical cancer involves multidisciplinary strategies. 
Various factor should be taken into consideration before any treatment is started. The 
locality of the cancer, categories of the cancer and not forgotten stages of the cancer 
including status of metastasis. The cervical cancer is usually treated with combination of 
surgery, radiotherapy and chemotherapy. The ultimate aim for any alternative treatment 
that targets cervical cancer cells is specifically to reduce unnecessary side effects and 
increase the efficiency of cancerous cell killing without affecting any surrounding healthy 
tissues. Since the treatment of cervical cancer involves continuous strategies, the cost for 
prolonged treatment is a major concern among patients and the government. Annually, it 
costs more than RM 300 million to manage cervical cancer from the prevention steps until 
handling the invasive cases (Zaridah, 2014). Apart from that, precautionary measures 
such as HPV vaccination before infected with cervical cancer should be taken into 
consideration among women regardless of age.  
 
 The most common treatment for cervical cancer is surgery, which is more 
preferred for early stage of cervical cancer (American Cancer Society, 2016). 
Nevertheless, cancer cells tend to attack healthy tissue nearby and potentially spread to 
distant, thus becoming metastatic. Most women with cervical cancer opt for uterus 
removal, thus unable to conceive after surgery (National Cancer Institute, 2017).  
 
 Other than that, radiotherapy is another option to treat cervical cancer. This 
treatment provides equal good results in terms of local control and survival for long term 
effect. Usually, in order to avoid the risk of recurrence, the option for radiation therapy 




2018). The disadvantages of this method are prolonged overexposure to the radiation 
beam and its effect on non – cancerous tissues. Low doses should be considered to avoid 
damage to healthy tissue but the accomplishment for cancer treatment would be delayed.  
  
 Apart from that, chemotherapy is also among the popular choice to battle cervical 
cancer. Generally, it is a treatment that uses cytotoxic anticancer drug. However, it does 
not distinguish between cancerous and healthy fast-growing cells in the body, such as hair 
and blood cells (Sayyad et al., 2009). The use of chemotherapy drugs are controversial. 
It is mainly related to drug resistance where the immune system of patients has been 
compromised with chemotherapy routine treatment (Yip et al., 2014). The current 
chemotherapy routine is unable to target specifically to cancer cells. The chemotherapy 
drugs kill both normal and cancerous cells due to the route of drug administration, which 
delivers the drugs to the whole body (Bhatla et al., 2018).  
 
 The most extensively used for chemotherapeutic anticancer drug is cisplatin, the 
first metal antitumor drug (Sayyad et al., 2009; Bhatla et al., 2018). A combination of 
cisplatin and radiotherapy restores p53 function and enhances the radiosensitivity of HPV 
16-positive SiHa cells (Huang et al., 2004). However, the significant role played by 
cisplatin is limited by its undesirable effect towards healthy cells and burdens patients 
with diarrhoea, fatigue and compromised immune system (Zhen et al., 2016). Eventually, 
the growth of cancerous cervical cells is weakened throughout treatment period with 
cisplatin, but the cells become resistant to the continuous treatment. This leads to possible 
reoccurrence.   
 
 Based on above situation, it is recommended to utilise chemopreventive agents 




progression of cancerous cell (Tsao et al., 2004). Chemopreventive agents originating 
from natural sources are believed to be more effective and relatively non-toxic towards 
suppressing HPV-positive cancer cells with lesser side effects compared to biochemical 
treatments (Zhen et al., 2016; Yaacob et al., 2015).  
 
2.3 Mechanism of cell death 
 
 Cytotoxic effect can be defined as inhibition of cancerous cell proliferation 
induced by certain agents that cause cell death. Mode of cell death can be implemented 




 Necrosis is a toxic process where the cells enter a passive situation, uncontrolled, 
unregulated and energy-independent mode of death. Traditionally, necrosis is considered 
the primary form of accidental cell death caused by inflammation. In necrotic cell death, 
external factors such as severe environmental perturbations and harsh physicochemical 
stimuli including mechanical factors, abrupt changes in temperature, osmotic pressure, 
excessively high concentration of chemical toxins and injury could damage the cell 
irreversibly, causing necrotic cell death (Su et al., 2016). This situation causes 
uncontrolled release of inflammatory cellular contents, thus resulting in changes of cell 
morphology. Cell swelling, formation of cytoplasmic vacuoles, formation of blebbed 
cytoplasm, and condensed swollen mitochondria are among typical morphological 
changes that occur during necrosis (Kerr et al., 1972; Elmore 2007; Zakaria et al., 2009). 
There is an influx of water and ions after the cell and its organelles swell and rupture. 




cascade, which is not desirable in treating cancer. Most of anticancer studies involving 
traditional medicinal plants prefer drug treatment that elicit less necrotic effect to avoid 




 Apoptosis is a type of active programmed cell death that plays a vital role in our 
body, including regulation of homeostasis. The apoptosis term was introduced by Kerr et 
al. (1972). In apoptosis, the cells shows morphological changes such as chromatin 
condensation, cytoplasmic cell shrinkage, fragmented DNA and apoptotic bodies. The 
mechanisms of apoptosis pathway involves a cascade of molecular events. Kumar and 
Clarks (2016) reported that treatment of cancer with chemotherapy works by triggering 
apoptotic pathways in the body. In apoptosis, there are two signaling pathways known as 
extrinsic and intrinsic pathways. In the extrinsic pathway, the damage of cell death 
involved extracellular effect (He et al., 2017) and is activated by death receptors of the 
tumor necrosis factor (TNF) receptor superfamily.  
 
 In the intrinsic pathway which also or known as mitochondrial pathways, there 
are intracellular damage such as DNA damage. This pathway is activated by signal 
transduction involving mitochondria and Bcl-2 protein family. He et al., (2017) stated 
that the ratio of Bax to Bcl-2 is an important indicator to assess apoptotic levels which 
high ratio of Bax/Bcl-2 presents apoptosis that induced by various factors including 
internal and external environmental factors. Bcl-2 inhibits the release of cytochrome C 
from mitochondria, which directly inactivates caspase-3 thus arrests apoptosis. 
Interestingly, Bax acts in an opposite manner by facilitating the release of cytochrome C 




 p53 is an anti-oncogene which is most highly involved in cancer. The p53 
participates in the regulation of cell cycle and later repair the damaged DNA. The cell 
cycle consists of four phases namely G1 (gap phase), S (DNA synthesis), G2 (gap phase) 
and M (mitosis). At G1 phase, transcription of cell cycle control genes and synthesizes 
protein begins while conducting series of checks before DNA synthesis. During S phase 
of cell cycle, DNA synthesis occurs and entire genome of cell is replicated whereas a gap 
phase G2/M allows newly replicated DNA continues to grow and prepare to enter M 
phase where cell divides its copied DNA into two daughter cells (Haron et al., 2019; 
Habli et al., 2017). The cell cycle system consists of several checkpoints that pause during 
each phase transitions to assess cellular conditions are proper for further growth and 
division. If the DNA damaged cannot be repaired, p53 acts by arrest cell cycle before 
entering mitosis and then induced apoptosis event in cancerous cells. 
 
 Another hallmark of both apoptosis pathways are the release of cytochrome c and 
activation of several caspases such as caspase -9, -8 and caspase -3. The key biochemical 
event involved in the induction of apoptosis is the activation of caspase-3, which is 
mediated through proteolytic cleavage of procaspase-3 via upstream caspases; caspase 
7/9 or caspase 8 (Kumar and Clarks, 2016). The activity of the caspase-3, which is an 
effect caspase involved in both intrinsic and extrinsic pathways of apoptosis, is expected 
to be altered in drug-induced cytotoxicity of cancer cells. Therefore, drugs that restore 
the apoptotic pathways have the potential to be effective treatment for tumors (Roslan et 
al., 2018; Yaacob et al., 2015). An ideal therapeutic goal for cancer treatment is to trigger 
selective apoptosis in tumor cells. Most of the antitumor drugs kill the cancer cells by 
stimulating the apoptotic pathway (He et al., 2017; Yaacob et al., 2015). Since targeting 




of C. nutans as an anticancer agent towards cervical cancer in this current study should 




























Table 2.1 Differences between apoptosis and necrosis (Kumar and Clarks, 2016; Su et 




Programmed cell death 
Controlled cell death 
Caused by intrinsic cellular response 
Detachment and engulfed by phagocytes 
Non – random DNA fragmentation 
Blebbing of plasma membrane 
Formation of apoptotic bodies 
Increase in cell volume  
Passive process 
Unregulated  
Accidental cell death  
Uncontrolled cell death  
Caused by severe environmental changes 
Recruitment of inflammatory cells 
Random DNA degradation  
Loss of plasma membrane integrity  
Leakage of cellular contents 

















2.4 Traditional medicinal plant 
 
2.4.1 Background  
 
 Medicinal plants are the basis of most traditional medicines. Local communities 
have a way of life that is interconnected with their surrounding environments. Their 
traditional knowledge including knowledge of species, ecological interactions and other 
environmental phenomena are obtained through observation, practice and adaptation. 
From here, there is widespread recognition of traditional medicinal plants such as the 
Tongkat Ali (Eurycoma longifolia), Hempedu Bumi (Andrographis paniculata) and 
others as well (National Policy on Biological Diversity, 2016). Hence, the traditional 
claim and belief in complementary medicine derived from medicinal plants should be 
explored and commercialised in order to curb cancer. In addition, the resistance of cancer 
cells towards commonly used treatment urges the discovery of novel components based 
on the routine from our old folks who used medicinal plants (Habli et al., 2017). Recently, 
this situation has been supported as scientific research on medicinal plants which is 
becoming more significant with several numbers of bioactive compounds being shown to 
exhibit variety of biological activities in vitro and in vivo. In cancer treatment itself, the 
majority of studies focus on the induced cytotoxicity from well-known plant-derived 
drugs such as vinblastine, topotecan, taxol, vincristine and vinflunine that are used 
clinically, worldwide (Habli et al., 2017; Liu et al., 2017; Nassan, 2015; ). For example, 
the vincristine which is derived from the leaves of the plant Catharanthus roseus has 
prominent antimicrotubule effects on the cells of metastatic urothelial carcinoma, able to 
treat hepatocellular carcinoma and breast cancer (Holmsten et al., 2016; Huang et al., 




certain level of cytotoxic reactions in patients such as neurotoxicity and abdominal 




 The common reason for refusal of conventional treatment to treat cancer including 
doubts about its safety. Cancer patients believe that alternative remedies such as 
medicinal plants are free from harmful effects despite no proper scientific analysis have 
been performed (Sayyad et al., 2009; Yaacob et al., 2015; Bruni et al., 2018). Certain 
medicinal plants are fragile, easily contaminated and degraded. Thus, to maintain their 
safety, quality and efficacy, they should be properly handled during preparation (Ibrahim, 
2004). The lack of scientific information including authentication of plant material, its 
active principle, efficacy of dosage and mechanism of action of the plants may lead to 
harmful effects on our bodies to the point of death (Khoo et al., 2018). Therefore, actual 
knowledge regarding properties of the plants, its safety and important information related 
to the suitable dosage should be established. Hence, there is an urgent need to fulfill and 
ameliorate the safety knowledge of medicinal plants with formal scientific 
documentation.  
 
2.5 Cervical cancer and traditional medicinal plant 
 
 Since our old folks, the trend showed that more than 60% of the currently used 
anticancer drugs are derived from natural sources such as plants, marine organisms and 
microorganisms (Alam et al., 2016; Choudari et al., 2013). Many previous studies have 
suggested the potential of medicinal plant as anticancer agents (Roslan et al., 2018; 




originated from medicinal plants that have been approved and commercialised for 
cervical cancer treatment, such as vinblastine, vincristine and paclitaxel (Habli et al., 
2017; Safarzadeh et al., 2014).  
 
 The use of traditional medicinal plant has become a trend in combating cervical 
cancer. For example, fisetin, a naturally occurring flavonoid, exhibited anticancer effect 
and induced apoptosis in HeLa cell lines, both in vitro and in vivo (Ying et al., 2012). 
Chloroform extract of C. nutans leaves has also been proven to inhibit the growth of HeLa 
cells (Yong et al., 2013). Curcumin, a natural compound originating from Curcuma longa 
was able to counteract the proliferative response of estradiol and induced apoptosis in 
cervical cancer cell, C33A (Singh and Singh, 2011). Interestingly, an aqueous extract of 
Ficus religiosa induces cell cycle arrest in SiHa cells and induced apoptosis in HeLa cells 
(Choudari et al., 2013). Recently, He et al. (2017) reported that liquiritin, a major 
constituents derived from Glycyrrhiza radix exhibited suppressive effects on the growth 
of SiHa cells in vitro by activating caspase-3 and on xenograft mice in vivo. 
 
2.5.1 Clinacanthus nutans 
 
 In Malaysia, one of the renowned medicinal plants is C. nutans which belongs to 
family of Acanthaceae. This plant is a native herb in tropical regions of Southeast Asia. 
Acanthaceae is one of the largest families of medicinal plants that have been utilised as 
effective traditional medicines. C. nutans is recognised by a few different vernacular 
names (Table 2.2), such as belalai gajah in Malaysia and Brunei (Zulkipli et al., 2017; 






Table 2.2 Vernacular names for Clinacanthus nutans 
Vernacular names Language Country Reference 
Belalai gajah Malay Malaysia, Brunei P’ng et al., 2013 
Sabah Snake Grass English Malaysia, Brunei Arullappan et al., 2014 
Dandang Gendis Indonesian Indonesia Hariana, 2013 
You Dun Cao Mandarin China Ying, 2013 





 This plant is a perennial herb with a rambling shrub that grows in nearly every 
habitat such as open or dense forests, scrublands, valleys and wet fields in tropical areas 
(Zulkipli et al., 2017; Alam et al., 2016; Yong et al., 2013). The stems are cylindrical, 
yellow when dry, densely striate and subglabrous. The shrub can grow up to 1 – 3 m tall 
and has branches (Zulkipli et al., 2017). The flower possessed dark red colour with a 
green base, however due to the leaves of C. nutans are commercially sold as beneficial 
health products, the plant is often harvested earlier before it can flower. Thus, C. nutans 
flowers are rare to be found.  
 
2.5.1 (a) The use of C. nutans in folk medicine 
 
 C. nutans has been used as a traditional medicine in China and Southeast Asia, 
mainly in Indonesia, Thailand and Malaysia. This plant has been appointed as medicinal 
herbs to be used in hospitals under the primary healthcare program in Thailand (Khoo et 
al., 2018). The old folks from Malaysia and Thailand utilised this plant widely for the 
treatment of skin rashes, insect and snake bites, herpes simplex virus (HSV) and varicella-
zoster virus lesions, mental tension, diabetes and rheumatoid arthritis (Tu et al., 2014). 
 
 Some studies reported that C. nutans leaves are consumed as juices, tea and fresh 
drinks (Fazil et al., 2016; Alam et al., 2016). Some old folks also eat the raw leaves of C. 
nutans. It is a common scenario in the local community that this plant is utilised in other 
forms such as tinctures, elixirs, poultices, powders and other formulations for chronic 
disease management or health-boosting purposes (Khoo et al., 2018). The leaves of C. 
nutans have gained its popularity as a supplement and medicine to treat various diseases 




cure cancer. However, its side effect is unknown. The healing effect has not been 
clinically tested in laboratory animals although the usage of this plant among the public 
is still growing (Asyura et al., 2016). 
 
2.5.1 (b) Phytochemistry of C.nutans 
 
 Many previous studies have shown that the aerial parts of plants such as leaves 
and stem contain a high amount of bioactive compound with anticancer properties 
including flavonoids, phenolic compounds, alkaloids and terpenoids, and these 
compounds can be extracted using specific organic solvents (Fazil et al., 2016; P’ng et 
al., 2013). Wanikiat et al. (2008) reported that the major phytochemical constituents of 
C. nutans are stigmasterol, β-sitosterol, lupeol, betulin, six known C-glycosyl flavones, 
vitexin, isovitexin, schaſtoside, isomollupentin, 7-O-β-gluco pyranoside, orientin, 
isoorientin, two glycoglycerolipids, a mixture of nine cerebrosides, five sulfur-containing 
glucosides and a monoacylmonogalactosylglycerol.  
 
 Sakdarat et al. (2008) extracted C. nutans with chloroform and 
chromatographically separated different varieties of chlorophyll a and chlorophyll b with 
a total of eight other compounds were isolated. However, only two compounds, 
trigalactosyl and digalactosyl diglyceride showed a good anti-herpes simplex virus (HSV) 
activity. Later, Sakdarat et al. (2009) isolated three more chlorophyll derivatives that were 
characterised by nuclear magnetic resonance (NMR) and found out that these compounds 
have anti-HSV activity.    
 
 More phytochemicals named eicosane, 1-nonadecene, heptadecane, 




nonadecyl heptafluorobutyrate, heneicosane, eicosayl trifluoroacetate, heptadecane and 
few more compounds with 1,2 – benzenedicarboxylic acid, mono are the major chemical 
constituents identified present in C. nutans using Gas Chromatography Mass 
Spectrohotometry  (GCMS), with relative peak area more than 28.6% (Yong et al., 2013). 
Other researchers have reported the presence of flavone C-glycosides as active 
constituents in C. nutans extracts by High Performance Liquid Chromatography (HPLC) 
analysis which the treatment led to a significant and dose-dependent reduction in tumor 
size and weight (Huang et al., 2015).  
 
2.5.1 (c) Biological activities of C. nutans  
 
 C. nutans extract has been proved to possess various biological activities. For 
example, the aqueous extract of C. nutans showed a potential antiangiogenic agent. The 
extract successfully suppressed endothelial cell (HUVEC) proliferation and migration by 
abolished the sprouting of vessels in aortic rings (Ng et al., 2018). Foong and colleagues 
(2017) reported that C. nutans aqueous extract possessed antiallergic property by 
inhibiting the early phase of IgE-mediated mast cell degranulation. C. nutans also 
exhibited antiviral activity towards HSV (Kunsorn et al., 2013). Polyherbal formulation 
of C. nutans with another traditional medicine also showed good wound healing activity 
where the ethyl acetate fraction of the formulation had the fastest wound healing activity 
with 89.28% inhibition (Aslam et al., 2016). The methanol extract of C. nutans also 
influenced peripherally and centrally mediated antinociceptive activity via the 
modulation of the opioid/NO-mediated (Rahim et al., 2016).  
 
 The antiproliferative and anticancer activities of C. nutans have also been widely 




scavenging and displayed significant proliferative effects on various cancer cells such as 
HeLa, HepG2, IMR32, K562, LS-174T, NCL-H23 and SNU-1 cells (Yong et al., 2013). 
Ng et al. (2017) showed that hexane and chloroform extracts of C. nutans have 
antiproliferative effect against A549 lung cancer cells, CNE1 nasopharygeal cancer cells 
and HepG2 liver cancer cells. The aqueous extract of C. nutans displayed potent 
antiangiogenic properties and has emerged as one of strategies to combat cancer (Ng et 
al., 2018). Treatment with C. nutans methanol extract demonstrated apoptosis induction 
in D24 melanoma cells (Fong et al., 2016). Roslan et al. (2018) proved that an active 
fraction from C. nutans is able to inhibit proliferation of HeLa cells by arresting at G1/S 
phase. A previous study reported that roots of C. nutans ethyl acetate extract promotes 
apoptosis induction on cervical cancer cells, HeLa via mitochondrial dependent manner 
(Teoh et al., 2016). There is limited study on the potential of C. nutans as an anticancer 
agent in animal models. Huang et al. (2015) reported that main components of C. nutans 
known as CN30, has a significant inhibitory effect on tumor volume and induced 
apoptosis in hepatoma cells. 
 
 Apart from being known as an anticancer agent, C. nutans has also been 
traditionally claimed to have antioxidant effects. The ethanol extract of C. nutans has the 
highest total phenolics content and total tannins content, followed by ethyl acetate, 
dichloromethane and hexane extracts, respectively (Sulaiman et al., 2015), the ethanol 
extract exhibited highest antioxidant activities. Total phenolics content was high in a 
fraction of C. nutans ethyl acetate which is responsible for attenuation of oxidative stress 
(Sarega et al., 2016). Le et al. (2017) also suggested that phytosterols isolated from the 
hexane extract of C. nutans exhibits immunomodulatory effects. Through LCM 
S analysis, flavonoids was identified in a polyherbal formulation that contained C. nutans 
which performed a potent role in wound healing (Aslam et al., 2016). UHPLC analysis 
